Ofatumumab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis: A Nationwide Cohort Study.
BACKGROUND AND OBJECTIVES B-cell-depleting therapy with anti-CD20 monoclonal antibodies is a highly effective and increasingly used treatment strategy for multiple sclerosis (MS); however, comparative effectiveness of anti-CD20 therapies is unclear. In this study, we aimed to evaluate the effectiveness of ofatumumab co...